Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310084 | 0.78 | NPC1 (0.39) | CYP1A2PSMB8TSHRLMNAALDH1A1 | |
| SCHEMBL514334 | 0.74 | CA12 (0.35) | CA12CA9 | |
| SCHEMBL767227 | 0.74 | ALDH1A1 (0.40) | CYP1A2TSHRLMNAALDH1A1CA12 | |
| SCHEMBL766942 | 0.74 | MAOA (0.32) | NOS1CA12CA9 | |
| SCHEMBL3378262 | 0.74 | MAOB (0.39) | CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL2517288 | 0.70 | ALDH1A1 (0.46) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL4455156 | 0.70 | GPR35 (0.36) | AHRTSHRALDH1A1CA12CA9 | |
| SCHEMBL5544202 | 0.69 | GABRA1 (0.43) | — | |
| SCHEMBL21296179 | 0.69 | ADORA3 (0.40) | CYP2A6TSHRALDH1A1 | |
| SCHEMBL767512 | 0.69 | CA1 (0.39) | CYP2A6TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2619200-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8394848-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1204126-C | Process for preparing pyridazin-2-one derivs. | SUMITOMO CHEMICAL CO (JP) | 2005-06-01 | — | — | CN | disclosed |
| EP-1137641-B1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-6500951-B1 | RING CLOSING A CARBOXYLIC ACID DERIVATIVE IN PRESENCE OF A NITROGEN CONTAINING AROMATIC COMPOUND AND A BORON COMPOUND; HIGH YIELD AND PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| CN-1334805-A | Process for preparing pyridazin-2-one derivs. | SUMITOMO CHEMICAL CO (JP) | 2002-02-06 | — | — | CN | disclosed |
| EP-1137641-A1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034249-A1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CYP1A2 4570/4885CYP2A6 4078/4885PSMB8 3740/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | CYP1A2 628/4885CYP2A6 3427/4885PSMB8 1700/4885 |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | CYP1A2 4570/4885CYP2A6 4078/4885PSMB8 3740/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP1A2 159/4885CYP2A6 215/4885PSMB8 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.